权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Analysis of dendritic cells after intra-bone marrow bone marrow transplantation

骨髓内骨髓移植后树突状细胞分析

基本信息

批准号：
17590362
负责人：
INABA Muneo
金额：
$ 2.24万
依托单位：
Kansai Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2006
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17590362/
关键词：
IBM-BMT Dendritic cells Serial BMT Hemopoietic stem cells Subset 骨髄内骨髄移植(IBM-BMT)

项目摘要

Long-term repopulating ability (LTRA) of hemopoietic stem cells (HSCs) has been assessed by serial bone marrow transplantation (BMT), and using this protocol, we provide evidence that intra-bone marrow BMT (IBM-BMT) can efficiently reconstitute the hemopoietic system with cells of donor origin, in contrast to conventional intravenous bone marrow transplantation (IV- BMT). The frequency of donor-derived progenitor cells having Lin^-/c-kit^+ phenotype or more primitive progenitors with immunophenotype of CD34^+/Sca-1^+ cells is higher in the recipients that had received bone marrow cells (BMCs) by IBM-BMT in the tertiary recipients than those received BMCs by IV-BMT. Furthermore, neither donor-derived progenitor cells nor mature hematolymphoid cells were detected in 〜25% of the tertiary recipients that had received BMCs by IV-BMT, indicating that progenitor cells can be efficiently maintained by IBM-BMT, but not IV- BMT. This was confirmed by the comparison of the progenitor cells between the recipients that had received BMCs by IBM-BMT or IV-BMT one year previously. In addition to these findings, conventional and plasmacytoid dendritic cells (cDCs and pDCs respectively) were normally differentiated even in the tertiary recipients by IBM-BMT, but not by IV-BMT. These findings clearly show that IBM-BMT is suitable for long-term maintenance of the hematolymphoid system of donor origin.

造血干细胞（HSC）的长期再增殖能力（LTRA）已通过连续骨髓移植（BMT）进行了评估，并且使用该方案，我们提供了证据表明，与传统的静脉内骨髓移植（IV-BMT）相比，骨髓内BMT（IBM-BMT）可以有效地用供体来源的细胞重建造血系统骨髓移植）。在三级受者中，通过 IBM-BMT 接受骨髓细胞 (BMC) 的受者中，具有 Lin^-/c-kit^+ 表型或具有 CD34^+/Sca-1^+ 细胞免疫表型的更原始祖细胞的频率高于通过 IV-BMT 接受 BMC 的受者。此外，在通过 IV-BMT 接受 BMC 的约 25% 的三级受者中，既没有检测到供体来源的祖细胞，也没有检测到成熟的血淋巴细胞，这表明 IBM-BMT 可以有效维持祖细胞，但 IV-BMT 则不行。通过对一年前通过 IBM-BMT 或 IV-BMT 接受 BMC 的接受者之间的祖细胞进行比较证实了这一点。除了这些发现之外，即使在第三代受者中，常规树突状细胞和浆细胞样树突状细胞（分别为 cDC 和 pDC）也可以通过 IBM-BMT 正常分化，但通过 IV-BMT 则不能。这些发现清楚地表明IBM-BMT适合长期维持供体来源的血淋巴系统。